Wim Guilliams to succeed Christophe Boizard as CFO of Ageas
Wim Guilliams to succeed Christophe Boizard as CFO of Ageas
Today, Ageas announces that, with effect 1 June 2023, and subject to the necessary regulatory approvals, Wim Guilliams will succeed Christophe Boizard who announced his intention to retire as CFO Ageas after a tenure of more than 11 years.
With Wim Guilliams, the current CFO of Ageas’s Belgian subsidiary AG Insurance, Ageas appoints an experienced executive with extensive financial knowledge and someone very familiar with the Group and the insurance sector.
Through the senior management positions he held before in various financial groups, and having led the implementation project of the new IFRS 17 accounting rules within Ageas, Wim is fully equipped to successfully lead the Ageas Finance community and to contribute to the further development of the company.
Wim Guilliams joined Ageas in 2015 as CFO of AG Insurance. Prior to this he held several executive and Board positions within KBC Group in Belgium and Eastern Europe, and within ING Insurance in Belgium.
As newly appointed CFO, Wim will also be proposed as a member of the Ageas Board of Directors at the General shareholders meeting of 17 May 2023. Wim’s appointment is subject to the approval of the National Bank of Belgium.
As of 1 January 2023, Wim will be appointed Deputy CFO of Ageas in order to initiate the transition with Christophe.
AG Insurance also announced this morning that a successor to Wim Guilliams as CFO of AG has been appointed. For more details, we refer to AG’s press release (French version).
HansDeCuyper,CEOAgeas: “I would like to take this opportunity to thank Christophe Boizard for his outstanding contribution in bringing Ageas to where it stands today.
During his tenure as CFO, Christophe built a solid financial team and has been incremental in the launch of the reinsurance business.
He also successfully issued several debt programmes and managed to strongly improve the Group’s financial ratings. Christophe is leaving us with a strong financial basis from which the Group can further develop.
As a colleague within the Executive Committee for the past 11 years, I would also like to thank Christophe for his sharp analysis and his focus on performance which has proven to be of great value in the development of the Group”
Wim Guilliams, CFO AG Insurance: “I'm honoured to be taking up the role of CFO of Ageas and thrilled to continue the excellent work of my predecessor. Ageas has a strong reputation for delivering and I look forward to working with the Group’s entire finance community to contribute to the achievement of our objectives and to Ageas's sustainable growth.”
Ageas is a listed international insurance Group with a heritage spanning almost 200 years. It offers Retail and Business customers Life and Non-Life insurance products designed to suit their specific needs, today and tomorrow. As one of Europe's larger insurance companies, Ageas concentrates its activities in Europe and Asia, which together make up the major part of the global insurance market. It operates successful insurance businesses in Belgium, the UK, France, Portugal, Turkey, China, Malaysia, India, Thailand, Vietnam, Laos, Cambodia, Singapore, and the Philippines through a combination of wholly owned subsidiaries and long term partnerships with strong financial institutions and key distributors. Ageas ranks among the market leaders in the countries in which it operates. It represents a staff force of about 40,000 people and reported annual inflows close to EUR 40 billion in 2021 (all figures at 100%).
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20228.12.2022 22:30:00 CET | Press release
Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights11/30/2022 94,137,145 Total gross of voting rights: 94,137,145 Total net* of voting rights: 93,966,891 * Total net = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.12.2022 22:00:00 CET | Press release
Company announcement – No. 57 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark and Boston, MA, U.S. December 8, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 64,919 divided into 64,919 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles o
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such8.12.2022 21:40:00 CET | Press release
COPENHAGEN, Denmark, December 8, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associateda)NamePaul Chaplin2.Reason for the notificationa)Position/status President and Chief Executive Officer of Bavarian Nordic A/S b)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument Identification codeWarrants DK0015
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer8.12.2022 21:40:00 CET | pressemeddelelse
KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse. 1.Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til dennea)NavnPaul Chaplin2.Årsag til indberetningena)Stilling/titelAdministrerende direktør i Bavarian Nordic A/Sb)Første indberetning/ændringFørste indberetning3.Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførendea)NavnBavarian Nordic A/Sb)LEI-kode2138006JCDVYIN6INP514.Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktionera)Beskrivelse af det finansielle instrument, instrumenttypen IdentifikationskodeTegningsoption
Bavarian Nordic iværksætter nyt incitamentsprogram for koncernledelsen og udvalgte medarbejdere8.12.2022 21:35:00 CET | pressemeddelelse
KØBENHAVN, Danmark, 8. december 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at bestyrelsen har besluttet at udstede tegningsoptioner til koncernledelsen og udvalgte medarbejdere i Bavarian Nordic koncernen. Som et nyt initiativ vil erhvervelsen (vesting) af tegningsoptioner for medlemmer af koncernledelsen være baseret på succesfuld opnåelse af relevante Key Performance Indicators (KPI’er). Beslutningen er truffet i henhold til generalforsamlingens bemyndigelser til bestyrelsen, jf. vedtægternes § 5b og 5c, og i overensstemmelse med selskabets vederlagspolitik. Der tildeles i alt 248.787 tegningsoptioner til medlemmer af koncernledelsen til en udnyttelseskurs på DKK 224,70 pr. aktie, svarende til markedskursen for Bavarian Nordics aktie på tildelingstidspunktet. Erhvervelse af tegningsoptionerne er betinget af forudgående opfyldelse af KPI’er, som fastsættes af bestyrelsen. Der tildeles i alt 683.264 tegningsoptioner til udvalgte medarbejdere i Bavarian Nordic koncernen til